The Role of Microglia in Human Diseases
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 2662
Special Issue Editor
Special Issue Information
Dear Colleagues,
Microglia are the primary immune cells of the central nervous system (CNS), similar to peripheral macrophages. They produce a strong proliferative response (microgliosis) to pathogens by changing morphology and migrating to the site of infection, where they destroy pathogens and remove damaged cells. These cells play specific roles in determining the progression and outcomes of essentially all CNS diseases. Thus, microglia have ceased to be viewed as an accessory to underlying pathologies and have now taken center stage as a therapeutic target. It would be very important to study microglia’s involvement in promoting or limiting the pathogenesis of different neuronal diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, Huntington’s disease, multiple sclerosis, X-linked adrenoleukodystrophy (X-ALD), lysosomal storage diseases (LSDs), etc.
When the microglia are activated, they take on an amoeboid shape and alter their gene expression, leading to the production of numerous potentially neurotoxic mediators, which are important in the normal functions of microglia and their production. In chronic neuroinflammation, microglia remain activated for an extended period, during which the production of mediators is sustained longer than usual. This secretion contributes to neuronal death.
It is crucial to study different activation phenotypes and other mechanisms of microglia in human brains.
In this Special Issue, we invite manuscripts on the role of microglia in different CNS diseases, other infectious diseases such as HIV-1 and HAND, and additional microglial involvement in the pathogenesis of diverse diseases and therapy-based research studies/reviews.
Dr. Ana Borrajo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
